Table 2.
Non-HLA antibody characteristics at time of index biopsy stratified according to HLA-DSA status.
| Antibodies | Entire Cohort |
HLA-DSA negative | HLA-DSA positive | P value* |
|---|---|---|---|---|
| (n = 62) | (n = 33) | (n = 29) | ||
| AT1R-Ab (U/mL), median (IQR) | 10 (8–15) | 9 (7–12) | 12 (9–17) | 0.013 |
| ≥ 10 U/mL; n (%) | 32 (51.6) | 12 (36.4) | 20 (69.0) | 0.010 |
| ETAR-Ab (U/mL), median (IQR) | 7 (5–13) | 6 (4–12) | 10 (6–17) | 0.031 |
| ≥ 10 U/mL; n (%) | 25 (40.3) | 10 (30.3) | 15 (51.7) | 0.086 |
| MICA-Ab (MFI), median (IQR) | 151 (71–379) | 134 (88–699) | 174 (57–599) | 0.253 |
| MFI >500; n (%) | 10 (16.1) | 3 (9.1) | 7 (24.1) | 0.108 |
| Vimentin IgG-Ab (OD), median (IQR) | 736 (591–952) | 739 (574–877) | 731 (602–1016) | 0.657 |
| OD > 1.852; n (%) | 3 (4.8) | 2 (6.1) | 1 (3.4) | 0.632 |
| Vimentin IgM-Ab (OD), median (IQR) | 362 (236–490) | 327 (231–550) | 379 (280–481) | 0.526 |
| OD > 0.790; n (%) | 6 (9.6) | 5 (15.2) | 1 (3.4) | 0.120 |
*Significance HLA-DSA positive vs. HLA-DSA negative cohort. Ab antibodies, HLA-DSA human leucocyte antigen donor-specific antibodies, AT1R-Ab angiotensin receptor type 1 antibodies, ETAR-Ab endothelin-1 type A receptor antibodies, MICA major histocompatibility complex class I polypeptide-related sequence A, MFI mean fluorescence intensity, OD optical density